Point72 Europe’s Apellis Pharmaceuticals APLS Stock Holding History

Point72 Europe’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-192,694	Closed	-$6.15M	–	125
2024 Q4	$6.15M	Buy	+192,694	New	+$5.79M	0.36%	69

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Europe's APLS Position: Q1 2025 in Review

Point72 Europe sold out of Apellis Pharmaceuticals (APLS) in Q1 2025, closing a stake of 192,694 shares — an estimated $6.15M sold.

Point72 Europe first reported a position in APLS in Q4 2024 and held it in 1 quarter. The position peaked at $6.15M in Q4 2024. 255 funds tracked by Wall St. Rank hold APLS as of Q1 2025.

Point72 Europe reported no remaining Apellis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Point72 Europe sold 192,694 Apellis Pharmaceuticals shares in Q1 2025, an estimated $6.15M.
Point72 Europe first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Point72 Europe's Apellis Pharmaceuticals position peaked at $6.15M in Q4 2024.
255 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2025.

Based on Point72 Europe's 13F filing for Q1 2025, filed 15 May 2025.